Key result
Automated patch-clamp electrophysiology revealed distinct, compound-specific micro-dynamics for sodium channel inhibitors such as riluzole, lidocaine, benzocaine, and bupivacaine.
Why the study?
Primary biophysical data are concentration-dependent, prompting the need to derive and quantify concentration-independent, compound-specific signature properties that reflect sodium channel inhibitor mechanisms of action.
An automated patch-clamp protocol can quantify compound-specific, concentration-independent biophysical properties of sodium channel inhibitors, providing parameters for kinetic modeling and predicting frequency-dependent drug action.
Should not yet change practice; leaves open whether kinetic signatures predict clinical use-dependence of sodium channel inhibitors.
We have developed an automated patch-clamp protocol that allows high information content screening of sodium channel inhibitor compounds. We have observed that individual compounds had their specific signature patterns of inhibition, which were manifested irrespective of the concentration. Our aim in this study was to quantify these properties. Primary biophysical data, such as onset rate, the shift of the half inactivation voltage, or the delay of recovery from inactivation, are concentration-dependent. We wanted to derive compound-specific properties, therefore, we had to neutralize the effect of concentration. This study describes how this is done, and shows how compound-specific properties reflect the mechanism of action, including binding dynamics, cooperativity, and interaction with the membrane phase. We illustrate the method using four well-known sodium channel inhibitor compounds, riluzole, lidocaine, benzocaine, and bupivacaine. Compound-specific biophysical properties may also serve as a basis for deriving parameters for kinetic modeling of drug action. We discuss how knowledge about the mechanism of action may help to predict the frequency-dependence of individual compounds, as well as their potential persistent current component selectivity. The analysis method described in this study, together with the experimental protocol described in the accompanying paper, allows screening for inhibitor compounds with specific kinetic properties, or with specific mechanisms of inhibition.
No takes yet. Share an insight, caveat, or question.
Pesti et al. (2021) studied this question. Sodium channel inhibitors (riluzole, lidocaine, benzocaine, bupivacaine) vs. Control (pre-drug baseline) was evaluated on Effective inhibitor potency (EIP) and micro-dynamics. Automated patch-clamp electrophysiology revealed distinct, compound-specific micro-dynamics for sodium channel inhibitors such as riluzole, lidocaine, benzocaine, and bupivacaine.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: